Loading patent…
AssigneesOsaka University, Tosoh Corporation
InventorsMotohide UEMURA, Norio NONOMURA, Takeshi UJIKE, Shohei MYOBA, Norihisa OHTAKE
Estimating the term…
A problem to be addressed by the present invention is to provide: a method for detecting bone metastasis of cancer (excluding castration resistant prostate cancer) in a simple and highly accurate manner; and a reagent that can be used in the method. Bone metastasis of cancer (excluding castration resistant prostate cancer) is detected by measuring an intact growth and differentiation factor 15 (GDF15) propeptide level, a GDF15 propeptide fragment level, and the total of an intact GDF15 propeptide level and a GDF15 propeptide fragment level in a sample. The above described method for detecting bone metastasis of cancer includes a method for detecting bone metastasis of prostate cancer other than castration resistant prostate cancer, renal cancer, lung cancer, breast cancer, thyroid cancer, pancreatic cancer, bladder cancer, colon cancer, melanoma, myeloma, or lymphoma. Further, the reagent for detecting bone metastasis of cancer (excluding castration resistant prostate cancer) includes an antibody that specifically recognizes GDF15 propeptide.
A method for detecting bone metastasis of cancer (excluding castration resistant prostate cancer), the method comprising measuring an intact growth and differentiation factor 15 (GDF15) propeptide level in a sample.
A method for detecting bone metastasis of cancer (excluding castration resistant prostate cancer), the method comprising measuring a GDF15 propeptide fragment level in a sample.
A method for detecting bone metastasis of cancer (excluding castration resistant prostate cancer), the method comprising measuring a total of an intact GDF15 propeptide level and a GDF15 propeptide fragment level in a sample.
(canceled)
Dependencies are inferred from the claim text.